Genomic Vision Selected for the Horizon 2020 Program’s ‘BeyondSeq’ Project with a Total Grant of €6 Million
09 Juin 2015 - 8:00AM
Business Wire
Molecular combing has been chosen as one of the
innovative technologies to analyze genetic mutations beyond next
generation sequencing
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a
molecular diagnostics company specialized in the development of
diagnostic tests for genetic diseases and cancers based on
molecular combing, today announces that it has been selected to
take part in the BeyondSeq (Genomic diagnostics beyond the
sequence) project, which has won a highly-selective tender within
the framework of Horizon 2020, the European Commission’s program
aimed at supporting research and innovation. This project,
coordinated by Tel Aviv University, brings together 6 other
participants, including a British company and Swedish, Israeli,
British and Belgian universities.
The goal of the BeyondSeq project, with a total budget of €6
million until 2019, is to bridge the technological gap between
cytogenetic diagnostics, which can identify chromosomal
aberrations, and next generation sequencing (NGS), which can detect
single base-pair mutations. Genomic Vision’s molecular combing
technology perfectly meets this need, by making it possible to
visualize single DNA molecules with a high definition and thus
identify structural variations in the genome, which are the cause
of numerous serious pathologies, and notably certain hereditary
types of cancer.
The mission of the participants in this project will be to
develop a set of tools, from systems for extracting long DNA
molecules and preparing samples through to analysis software to
interpret genetic information.
Applications will address a number of indications such as
bacterial infections and antibiotic resistance, hematological
malignancies, early diagnosis of colorectal and lung cancer, as
well as Spinal Muscular Atrophy (SMA). Genomic Vision will thus
bring its expertise in the detection of structural variations
involved in SMA (deletion of both copies of the SMN 1 gene), and
will notably be responsible for developing a test that is capable
of identifying “2+0” carriers (carriers of both copies of the SMN 1
gene on a chromosome), which are undetectable using existing
techniques.
Yuval Ebenstein, the project’s coordinator at Tel Aviv
University, says: “BeyondSeq is a project that is emblematic of
European genetic research, whose objective is to develop new
technologies to provide complementary solutions to sequencing and
thus analyze the hidden dimension of genetic mutations. Our
workgroup consists of experts in this field, and we are delighted
that a company such as Genomic Vision – with its unique molecular
combing technology that is capable of studying individual DNA
molecules – should be a part of it.”
Aaron Bensimon, Genomic Vision’s co-founder and Chairman,
adds: “As a world leader in the manipulation of individual
molecules of DNA, it is totally natural that Genomic Vision should
take part in this ambitious research project. This collaboration is
completely in line with the technological development strategy that
we are implementing in accordance with the commitments we made at
the time of our IPO. Genomic Vision will provide this prestigious
consortium with its industrial experience while benefiting from the
consortium’s academic know-how in order to drive its technology
forward towards a new generation of molecular combing.”
Visit our new website:
www.genomicvision.com
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics
company specialized in the development of diagnostic tests for
genetic diseases and cancers based on molecular combing. Using this
innovative technology that allows the direct visualization of
individual DNA molecules, Genomic Vision detects quantitative and
qualitative variations in the genome that are at the origin of
numerous serious pathologies. The Company is developing a solid
portfolio of tests that notably target breast cancer and cancer of
the colon. Since 2013, the Company has marketed the CombHeliX FSHD
test for identifying a myopathy that is difficult to detect,
Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks
to a strategic alliance with Quest Diagnostics, the American leader
in diagnostic laboratory tests, and in France. Genomic Vision has
been listed on Compartment C of Euronext Paris since April
2014.
ABOUT MOLECULAR COMBING
DNA molecular combing technology considerably improves the
structural and functional analysis of DNA molecules. DNA fibers are
stretched out on glass slides, as if “combed”, and uniformly
aligned over the whole surface. It is then possible to identify
genetic anomalies by locating genes or specific sequences in a
patient’s genome using genetic markers, an approach developed by
Genomic Vision and patented under the name Genomic Morse Code. This
exploration of the entire genome at high resolution via a simple
analysis enables the direct visualization of genetic anomalies that
are undetectable by other technologies.
For further information, please go to www.genomicvision.com
Member of CAC® Mid & Small, CAC®
All-Tradable and EnterNext© PEA-PME 150 indexes
DISCLAIMER
This press release contains certain forward-looking statements
concerning Genomic Vision and its business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the prospectus on which the French Financial Market
Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to
the development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for GENOMIC VISION shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150608006690/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorNewCapInvestor Relations
/ Strategic CommunicationsDušan Orešanský / Emmanuel Huynh+33 1 44
71 94 92gv@newcap.fr
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024